Dysbindin may promote tumor growth in pancreatic cancer by activating the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway, and dysbindin overexpression is correlated with a poor prognosis for pancreatic ductal adenocarcinoma [15]. Here, DTNBP1 is linked to familial pancreatic carcinoma.